Lumos Pharma, Inc. (LUMO)

Lumos Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.53	2.05	1.52	0.23	0.17	0
Revenue Growth (YoY)	-27.48%	34.67%	562.17%	36.90%	-	-
Gross Profit	1.53	2.05	1.52	0.23	0.17	0
Selling, General & Admin	15.99	16.57	15.71	15.33	17.27	4.15
Research & Development	24.98	22.1	17.86	16.25	9.21	5.67
Operating Expenses	40.97	38.67	33.56	31.58	26.47	9.82
Operating Income	-39.44	-36.61	-32.04	-31.35	-26.3	-9.82
Other Expense / Income	-2.28	-2.55	-0.97	-0.28	-6.67	-0.11
Pretax Income	-37.16	-34.06	-31.08	-31.07	-19.64	-9.71
Income Tax	-0.03	-0.03	-0.01	-0.64	-13.97	0
Net Income	-37.13	-34.03	-31.06	-30.43	-5.66	-9.71
Preferred Dividends	0	0	0	0	0.65	3.04
Net Income Common	-37.13	-34.03	-31.06	-30.43	-6.31	-12.75
Shares Outstanding (Basic)	8	8	8	8	7	1
Shares Outstanding (Diluted)	8	8	8	8	7	1
Shares Change	-1.64%	-2.73%	0.47%	22.97%	420.42%	-68.48%
EPS (Basic)	-4.59	-4.18	-3.71	-3.65	-0.93	-9.79
EPS (Diluted)	-4.59	-4.18	-3.71	-3.65	-0.93	-9.79
Free Cash Flow	-34.79	-31.1	-26.64	-29.68	9.47	-9.09
Free Cash Flow Per Share	-4.29	-3.82	-3.18	-3.56	1.40	-6.98
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-2586.30%	-1785.18%	-2103.74%	-13629.13%	-15656.55%	-
Profit Margin	-2434.69%	-1659.39%	-2039.53%	-13230.43%	-3758.33%	-
Free Cash Flow Margin	-2281.44%	-1516.09%	-1749.44%	-12903.48%	5638.69%	-
EBITDA	-37.12	-34.02	-31.03	-30.85	-19.05	-9.67
EBITDA Margin	-2434.16%	-1658.65%	-2037.16%	-13412.61%	-11340.48%	-
Depreciation & Amortization	0.04	0.04	0.05	0.22	0.58	0.04
EBIT	-37.16	-34.06	-31.08	-31.07	-19.64	-9.71
EBIT Margin	-2436.59%	-1660.80%	-2040.38%	-13506.96%	-11688.10%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).